Photo of Thato lketleng

Thato lketleng

PhD Student 

Africa Centre for Population Health and
University of KwaZulu Natal

PhD fellow - Botswana Harvard AIDS Institute Partnership

PhD fellow – H3ABioNet

Thato Iketleng

P.O. Box 2559AAD
Poso House
GaboroneBotswana

E. This email address is being protected from spambots. You need JavaScript enabled to view it.

E. This email address is being protected from spambots. You need JavaScript enabled to view it.

T. +27 (0) 603260183

T. +267 (0) 71833615

1. Souda S, Gaseitsiwe S, Georgette N, Powis K, Moremedi D, Iketleng T, et al. No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana. Journal of acquired immune deficiency syndromes (1999). 2013 Aug 15;63(5):572-7. PubMed PMID: 23542639. Pubmed Central PMCID: PMC3762949. Epub 2013/04/02. eng.

M. tuberculosis treatment, transmission and drug resistance

Thato is a PhD student at the University of KwaZulu Natal - Africa Centre for Population Health. He holds a BSc in Molecular Biology and Biomedical Sciences from Murdoch University, Perth, Australia and an MSc in Medical Microbiology, Immunology with Molecular Biology from Kilimanjaro Christian Medical University College, Tanzania. He is a recipient of the H3ABioNet PhD fellowship through Botswana Harvard AIDS Institute Partnership. Thato has held several positions with Botswana Harvard AIDS Institute including, Coordinator for Specimen Management. He has been a recipient of the FORGARTY International Clinical Research Scholar fellowship.

His research involves using Genomics and Bioinformatic approaches to understand M. tuberculosis drug resistance and transmission dynamics in rural KwaZulu-Natal. It involves using both Sanger and next generation sequencing technologies and comparing them with culture based drug susceptibility testing for M. tuberculosis drug resistance determination. His goal is to generate M. tuberculosis whole genomes locally from both culture and most importantly directly from sputum as this would significantly shorten the turn around time to susceptibility results. If this is successful, he hopes that it will eventually improve drug resistant TB patient management.